Annual report [Section 13 and 15(d), not S-K Item 405]

Summary of Significant Accounting Policies (Tables)

v3.26.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2025
Summary of Significant Accounting Policies  
Schedule of significant expense categories

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Year Ended

​

​

December 31, 

​

December 31, 

​

  ​ ​ ​

2025

  ​ ​ ​

2024

Operating expenses:

​

​

​

​

​

​

Acquired in-process research and development

​

$

12,030,389

​

$

—

Clinical

​

​

7,251,179

​

​

1,153,345

Chemical, manufacturing and controls

​

​

1,027,799

​

​

710,055

Research and preclinical

​

​

58,198

​

​

505,750

Regulatory

​

​

43,477

​

​

20,065

Other research and development costs

​

​

1,455,029

​

​

1,141,698

Total research and development

​

​

21,866,071

​

​

3,530,913

General and administrative expenses

​

​

6,102,374

​

​

8,696,335

Total operating expenses

​

$

27,968,445

​

$

12,227,248

Loss on debt conversion with related party

​

​

6,134,120

​

​

—

Interest (income) expense, net

​

​

(96,938)

​

​

92,192

Loss on fixed asset disposal

​

​

2,731

​

​

—

Exchange loss, net

​

 

27,916

​

 

30,787

Net loss before income taxes

​

$

34,036,274

​

$

12,350,227